* CHMP recommends lifting of treatment restrictions for Neupro® in Europe * Recommends allowing Neupro® to be available to all patients with Parkinson’s disease * Recommends allowing Neupro® to be launched for the treatment of moderate to…
Biopharmaceuticals, Neurology, Regulatory
UCB, Neupro, rotigotine transdermal patch, Parkinson’s disease

If you are a sales professional or want to become one, or if you are looking for a new sales job, you will face one of the toughest interview processes of any job seeker.
0 Comments on “UCB receives CHMP positive opinion on bringing Neupro(R) back to all patients in Europe”
Leave a Comment